Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions. It engineers vibegron (RVT-901), an investigational oral β3-adrenergic agonist for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. The company was merged into Sumitovant Biopharma.